Shoreline Biosciences is developing allogeneic, off-the-shelf, targeted, and standardized immunotherapies using intelligently engineered induced Pluripotent Stem Cell (iPSC)-derived NK cells and macrophages for serious diseases. Shoreline’s proprietary cell therapy platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced persistence and tumor killing. In addition, the company aims to restore tissue homeostasis and function by introducing engineered macrophages for fibrotic and inflammatory pathologies. Shoreline has developed expertise that we expect will allow for efficient and cost-effective manufacturing of these cells.
We are committed to scientific and clinical excellence and are passionate about bringing transformative therapies to patients in critical need.